Jennifer has more than 16 years’ commercial leadership experience in the diagnostics and life sciences industries
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has appointed Jennifer Murphy as Senior Vice President of Global Commercial Operations. In her new role, Jennifer will be responsible for building and growing the global commercial programs for all BioIVT’s product lines and services.
“We are delighted that Jennifer is joining BioIVT. She has a wealth of life sciences leadership and sales expertise…
Boom in start-ups and spin-outs drives growth for UK life sciences as investment almost doubles
● New report shows number of UK life science start-ups in 2016-20 increased by 24% on the previous reporting period to a total of 681, at almost double the rate of ten years ago.
● £20 billion worth of capital is looking to invest in UK life science real estate.
● Total investment in the UK life sciences sector reached a record £4.5 billion in 2021, nearly double the £2.8 billion invested in 2020 (BioIndustry Association).
A joint report published by JLL and leading life sciences developer-…
Boyds, the global drug development consultancy, has reported another strong year of growth, with an increase in excess of 20 percent year-on-year in annual revenue in the wake of increased demand for its specialist expertise across the UK, US, and Europe.
Since the opening of Boyds’ US office in Pennsylvania last year, headed by Katy Rudnick, the company has recorded significant growth in US revenue, which now accounts for approximately 30 percent of its total revenue.
Boyds’ global reputation for its work in cutting-edge products including cell and gene therapies has led to a steady…
SOMERSET, N.J. – April 6, 2022 — Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.) of a biologics development and manufacturing facility currently under construction near Oxford, U.K.
Catalent plans to invest up to $160 million (£120 million) to complete the building of the facility and equip it with state-of-the-art capabilities for the development…
AMSBIO announce the addition of several new products to its growing range of magnetic bead based nucleic acid extraction kits for pathogen detection.
The MagSi-NA Pathogens MSP (Multiple Sample Pooling) kit sets a new benchmark for automated isolation of nucleic acids (RNA and DNA) from respiratory samples.
Sample pooling is useful in times of high testing and low infection prevalence where traditional sample screening methods are not cost-effective. This will be particularly effective in school and healthcare settings where periodic and comprehensive testing of large numbers of…
AMSBIO announces the launch of the QuicKey Pro™ range of ELISA kits – new easy-to-use assays that require just one step of washing, and one step of sample addition, resulting in a whole experiment taking only 90 minutes.
Compared with traditional ELISA kits, the total procedure time using a QuicKey Pro™ ELISA kit is reduced by 1-2 hours, resulting in significant gains in experimental efficiency.
Based upon proprietary Competitive and Sandwich technologies – QuicKey Pro™ ELISA assay kits allow researchers to choose the optimal ELISA format to measure their specific analyte of interest in…
AMSBIO has introduced further essential tools for SARS-CoV-2 researchers to help decipher the COVID-19 B.1.1.529 variant.
New to the AMSBIO range are recombinant proteins, easy-to-perform assay kits, Omicron pseudotyped lentiviruses and spike neutralizing antibodies for use in functional assays to block SARS-CoV-2 spike protein and ACE2 binding.
Screening for small molecule and antibody inhibitors is an important factor in assisting the discovery of treatments and vaccines for COVID-19 variants. ACE2, Spike, and the 3CL/Main protease are all potential therapeutic targets for the SARS-…
SOMERSET, N.J. – March 16, 2022 — Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the completion of a $30 million (€27 million) project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging. The site will further expand Catalent Biologics’ global network, with early phase integrated clinical development through…
Transaction expands BioIVT’s donor network and increases its capacity to provide fresh whole blood, plasma, serum, and red blood cells for drug and diagnostic development
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Tennessee Blood Services (TBS), a commercial blood bank located in Memphis, Tennessee. TBS is FDA-registered to collect whole blood and blood products for diagnostic use by manufacturers and research facilities worldwide.
“We are delighted the TBS team is joining BioIVT and will…